The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Open accessPublished version of a preprint
Abstract
The CRISPR-Cas9 system is a powerful tool for genome editing, which allows the precise modification of specific DNA sequences. Many efforts are underway to use the CRISPR-Cas9 system to therapeutically correct human genetic diseases 1-6. The most widely used orthologs of Cas9 are derived from Staphylococcus aureus and Streptococcus pyogenes 5,7. Given that these two bacterial species infect the human population at high frequencies 8,9, we hypothesized that humans may harbor preexisting adaptive immune responses to the Cas9 orthologs derived from these bacterial species, SaCas9 (S. aureus) and SpCas9 (S. pyogenes). By probing human serum for the presence of anti-Cas9 antibodies using an enzyme-linked immunosorbent assay, we detected antibodies against both SaCas9 and SpCas9 in 78% and 58% of donors, respectively. We also found anti-SaCas9 T cells in 78% and anti-SpCas9 T cells in 67% of donors, which demonstrates a high prevalence of antigen-specific T cells against both orthologs. We confirmed that these T cells were Cas9-specific by demonstrating a Cas9-specific cytokine response following isolation, expansion, and antigen restimulation. Together, these data demonstrate that there are preexisting humoral and cell-mediated adaptive immune responses to Cas9 in humans, a finding that should be taken into account as the CRISPR-Cas9 system moves toward clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, long-term expression of genome editing molecules may expose patients to undesired off-target editing or immune reactions 66,67 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pre-existing Cas9 antibodies and reactive T-cells have been detected in humans exposed to pathogenic bacteria harboring CRISPR systems, although it is unknown whether these are present at concentrations sufficient to trigger an immune response to the genome editing enzymes 66,104 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it is unknown whether these are present at concentrations sufficient to trigger an immune response to the genome editing enzymes 66,104 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other factors affecting clinical applications of genome editing include the immunogenicity of bacterially-derived editing proteins, the potential for pre-existing antibodies against CRISPR components to cause inflammation and the unknown long-term safety and stability of genome editing outcomes.”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Another consideration for CRISPR/Cas9-based systems for retinal gene editing is the potential for a heightened adaptive immune response given the bacterial origin of the Cas9 enzyme and high prevalence of pre-existing immunity (Charlesworth et al., 2019).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Charlesworth et al., 2019
In the citing paper
“A study involving 125 healthy adult human blood donors in the USA with a median age of 43 reported pre-existing anti-SaCas9 antibodies and anti-SpCas9 antibodies in 78% and 58% of the total samples, respectively.”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [24]
In the citing paper
“Among the tested donors, 78% had SaCas9-specific T-cells and 67% were positive for SpCas9-specific T-cells.”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [24]
In the citing paper
“While there are discrepancies regarding the exact prevalence of these antibodies in humans, a majority of the general population may exhibit preexisting α-Cas93.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“Furthermore, a high prevalence of preexisting cellular immunity against Cas9 (Cas9-reactive T-cells) has also been identified2–4.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“multiple groups have reported high frequencies (>60% of patients) of Cas9 reactive T-cells in humans2–4.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“This may explain the lower raw ELISA A450 values we observed compared with previous work (Table 1)3.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“CRISPR-Cas9 is a promising therapeutic tool that allows genetic target-specific cleavage and editing (111).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [111]
In the citing paper
“One concern is that the prevalence of anti-SaCas9 antibodies and T-cell in humans are reported to be 78% (111).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Staphylococcus aureus Infections
Lowy, F. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390806 · Cited by 6,018
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature · doi:10.1038/nature20565 · Cited by 1,150
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Pukelsheim, F. (1994) · The American Statistician · doi:10.1080/00031305.1994.10476030 · Cited by 1,072
Cited by
Sorted by citations
Items 801–900 of 1,000
A Translational Roadmap for Neurological Nonsense Mutation Disorders
Li, J., Zhu, Z., & Xu, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031418 · Cited by 2
Genome editing in aquaculture: From bench to commercial deployment
Kho, K. H., & Sukhan, Z. P. (2026) · Aquaculture · doi:10.1016/j.aquaculture.2026.743871 · Cited by 2
My, B., Lia, A., Rizzo, L., Maiorano, G., Galeone, A., Palamà, I. E., & Gigli, G. (2026) · iScience · doi:10.1016/j.isci.2026.115422 · Cited by 2
Considerations for early life genetic therapies in cystic fibrosis
Cooney, A. L., Thornell, I. M., Pezzulo, A. A., Fischer, A. J., Cook, D. P., Alaiwa, M. H. A., Ode, K. L., Uç, A., Zabner, J., Ryan, A. L., et al. (2026) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00022.2026 · Cited by 2
Siddika, A., Rousseau, J., Veillette, F., Bouchard, C., Lu, Y., & Tremblay, J. P. (2026) · Cells · doi:10.3390/cells15100852 · Cited by 2
Molecular and Genetic Aspects of Lipid Metabolism Disorders and Potential Targets for Gene Therapy
Akhmetzyanova, E. R., Викторовна, Т. А., Gallyamov, D. R., Rizvanov, A. A., & Mukhamedshina, Y. O. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.2.195 · Cited by 3
Ju, Z., Chen, L., Zhu, X., Cai, Y., Wei, S., Zhou, X. Y., Shi, Y., Liu, C., Huang, C., Bi, S., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx7857 · Cited by 2
Saberian, M., Roosta, A., & Afrisham, R. (2026) · Gene · doi:10.1016/j.gene.2026.150246 · Cited by 2
CRISPR-based gene editing for antimicrobial resistance control in human medicine
Alvi, A. A., Hussain, M., Noureen, S., Malik, Z. A., Zahoor, S., Jamil, A., Mohsin, M. A., Azeem, A., Javaid, H., & Hassan, Z. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04988-2 · Cited by 2
Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer
Huang, F., Yuan, F., Li, K., Cui, Y., Li, L., Ye, W., Cui, Z., Yan, J., Chen, Q., Nicchitta, C. V., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01720-9 · Cited by 2
Eskandani, N. A., Mirzaee, D., Farani, M. R., Hatami, A., Hatami, M., Ghasemzaei, M., Ghoreishian, S. M., Hwang, S.-K., & Huh, Y. S. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115921 · Cited by 2
Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives
Yang, M., Song, Y., Wang, Z., Chao, K., Li, L., Zhang, X., Duan, X., Yu, C., Xue, R., & Zhao, J. (2026) · MedComm · doi:10.1002/mco2.70791 · Cited by 3
Ng, C. X., Mustafa, S., Yap, X. Y., & Lee, S. H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1888734 · Cited by 2
Base editing for precision therapeutics
Regmi, M., Ma, K., Bi, C., Zhang, X., Zhao, D., Yu, L., Huihui, Y., Wang, N., & Yang, C. (2026) · Cell Genomics · doi:10.1016/j.xgen.2026.101298 · Cited by 2
Quan, A. T. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102892 · Cited by 2
She, L., Liang, Z., Zou, Q., & Huo, Y. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.6c00386 · Cited by 2
Multicellular systems to translate somatic cell genome editors to human
Hernandez‐Gordillo, V., Casolaro, T. C., Ebrahimkhani, M. R., & Kiani, S. (2020) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2020.100249 · Cited by 2
Ortuño-Fajardo, M. P., Chacón-Halabi, J. R., Flores-Espinoza, M. P., & Aguilar-Bravo, R. (2021) · Revista Tecnología en Marcha · doi:10.18845/tm.v34i1.4830 · Cited by 2
Anti-Cas9 immunity: A formidable challenge for muscle genome editing
Lagor, W. R. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.12.006 · Cited by 2
A Primer on Gene Editing: What Does It Mean for Pathologists?
Cushman‐Vokoun, A. M., Schmidt, R. J., Hiemenz, M., Fung, M. K. Y., Zhang, B. M., Bradshaw, G., Gandhi, M. J., Yao, J., Yohe, S. L., Beckman, A. K., et al. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0410-cp · Cited by 2
CRISPR: the Janus god of modern science
Khare, P., Mandal, S., Verma, A. K., Parashar, D., Jadhav, K., & Gupta, S. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91808-4.00006-7 · Cited by 2
Monteferrario, D., David, M., Tadi, S. K., Zhou, Y., Marchetti, I., Jeanneau, C., Saviane, G., Dupont, C. F., Martelli, A. E., Truong, L. N., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101255 · Cited by 2
Saha, P., Hasib, M. A., Halder, B., Sultana, S., & Rafe, M. R. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106589 · Cited by 2
Preclinical development of genome editing to treat Duchenne muscular dystrophy by exon skipping
Padmaswari, M. H., Agrawal, S., & Nelson, C. E. (2025) · Journal of Neuromuscular Diseases · doi:10.1177/22143602251326993 · Cited by 2
AI expands the repertoire of CRISPR-associated proteins for genome editing
Notin, P. (2025) · Nature · doi:10.1038/d41586-025-02135-3 · Cited by 2
Montesinos‐Rongen, M., Sánchez-Ruiz, M., Siebert, S., Winter, C., Siebert, R., Brunn, A., & Deckert, M. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0049 · Cited by 2
Precise Editing and Functional Verification of Pine Disease Resistance Genes
Deng, Y., & Li, M. (2024) · Molecular Plant Breeding · doi:10.5376/mpb.2024.15.0015 · Cited by 2
Efficiency of genome editing using modified single-stranded oligodeoxyribonucleotides in human cells
Kim, S., Matsushita, Y., Katagiri, T., & Maseda, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-94071-5 · Cited by 2
Westarp, P., Keller, T., Brand, J. S., Horvat, S., Albrecht, K., Beisel, C. L., & Gröll, J. (2025) · Discover Nano · doi:10.1186/s11671-025-04316-5 · Cited by 2
Emerging therapeutic applications of CRISPR genome editing
Qasim, W. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20190010 · Cited by 2
Recent advances towards gene therapy for propionic acidemia: translation to the clinic
Barry, M. A. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1635883 · Cited by 2
Optimization of Cas9 RNA sequence to reduce its unexpected effects as a microRNA sponge
Jiang, J., Zeng, T., Zhang, L., Fan, X., Jin, Q., Ni, H., Ye, Y., Cheng, L., Li, L., Wang, L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01604-x · Cited by 2
Self-citationProspects for using CRISPR-Cas9 system in the treatment of human viral diseases
Зиганшин, А. М., Рамильевич, М. А., Абдурахманович, О. М., Мудров, В. А., & Khalitova, R. S. (2023) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2023-8.1.5 · Cited by 2
Genome-Editing – Gentherapie 2.0 oder nur eine Wunschvorstellung?
Fehse, B., Grünewald, J., & Petri, K. (2023) · Springer eBooks · doi:10.1007/978-3-662-67908-1_7 · Cited by 2
Emerging CRISPR/Cas9 applications for T-cell gene editing
Preece, R., & Georgiadis, C. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20180144 · Cited by 2
Food Transformation Technology in Paolo Bacigalupi’s The Windup Girl and What It Means for Us
Lee, Y.-H. (2019) · Kritika Kultura · doi:10.13185/kk2020.0033/3430 · Cited by 2
Coevolutionary Couplings Unravel PAM-Proximal Constraints of CRISPR-SpCas9
Li, Y., de la Paz, J. A., Jiang, X., Liu, R., Pokkulandra, A. P., Bleris, L. G., & Morcos, F. (2019) · Biophysical Journal · doi:10.1016/j.bpj.2019.09.040 · Cited by 2
Gene editing technology for improving life quality: A dream coming true?
Ramezankhani, R., Minaei, N., Haddadi, M., Torabi, S., Hesaraki, M., Mirzaei, H., Vosough, M., & Verfaillie, C. M. (2020) · Clinical Genetics · doi:10.1111/cge.13794 · Cited by 2
Attenello, F. J. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw5328 · Cited by 2
Weakly immunogenic CRISPR therapies
Wilson, E., & Anderson, K. S. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0463-7 · Cited by 2
DNA Recognition/Processing | Zinc Fingers: Structure and Design
Isalan, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21266-1 · Cited by 2
Kumar, S., & Venkat, S. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1376509 · Cited by 2
Han, X., Ji, G., Wang, N., Yi, L., Mao, Y., Deng, J., Wu, H., Ma, S., Han, J., Bu, Y., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04301-5 · Cited by 1
Genome Editing in Potato Using CRISPR/Cas Technology: Applications and Challenges
Beniwal, D., Chauhan, S., & Dhillon, H. K. (2024) · Genetics. · doi:10.5772/intechopen.1003940 · Cited by 1
Purohit, S., Nayak, A., Rani, V., & Jain, C. K. (2025) · Advances in Science, Technology & Innovation/Advances in science, technology & innovation · doi:10.1007/978-3-031-80189-1_12 · Cited by 1
Lu, J., Gao, Y., Li, Q., Jiao, Y., Bian, Y., Lin, H., Lei, X., Wang, W., Li, Z., & Wang, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104867 · Cited by 1
CRISPR: a precise genome editing strategy for the treatment of hepatocellular carcinoma
Mukherjee, S., & Kumar, M. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2606090 · Cited by 1
Epigenome editing strategies: technological progress and in vivo applications
Morita, S., Horii, T., & Hatada, I. (2026) · BMC Methods · doi:10.1186/s44330-026-00069-4 · Cited by 1
Modalities of vision restoration in optic neuropathies and retinal disease
Rubin, B. R., Lavinsky, F., Cain, R., Kuriyan, A. E., Wollstein, G., Zambrano, R., & Schuman, J. S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101474 · Cited by 1
Ciganek, I., Delehedde, C., Galy, A. H. M., Cogné, M., Rameix, N., Bordeianu, C., & Pichon, C. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103334 · Cited by 2
CRISPR-based therapeutics to combat respiratory viral infections
Baindara, P., & Dinata, R. (2026) · Discover Viruses. · doi:10.1007/s44370-026-00045-0 · Cited by 1
The evolution of AI-integrated genome editing and its challenges
Wong, M. T. J., Zulkifli, N. D., Ravichandran, T., Vasodavan, K., Bin-Alshaibah, O., Himel, G. M. S., Achuthan, A., Anthonysamy, M. A., & Das, K. T. (2026) · Mammalian Genome · doi:10.1007/s00335-026-10248-x · Cited by 1
Chen, S., Hsiao, S., Xie, T., Chen, D., Chen, N., Jiang, J., Li, J., Wu, Y., & Liao, J. (2026) · Nature Communications · doi:10.1038/s41467-026-74624-6 · Cited by 1
Balancing efficiency, safety, and scalability in therapeutic genome editing delivery
Shaji, N., Firdous, S., Anbazhagan, S. V., Ganesh, R., Kumari, N., & Kumar, V. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108643 · Cited by 2
The landscape of genetic medicines for in vivo T cell reprogramming
(1953121), J. B. S., Lemgart, V. T., Kulkarni, J. A., & Witzigmann, D. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115940 · Cited by 1
Self-citationOn-target and off-target activities of CRISPR therapeutics across scales
Magdy, M., Gibson, J. R., Dhungana, A., Herring‐Nicholas, A., Cottle, R. N., & Josephs, E. A. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.07.015 · Cited by 1
Mahdy, A., ElBakry, O. M., Eladl, O., Etman, A. E., Attia, Y. A. M., Abdallah, A. K., Abdelmalek, M. A., Helal, M. W., Hamdy, M., El-Sayyad, G. S., et al. (2026) · Nanotechnology · doi:10.1088/1361-6528/ae9bcd · Cited by 1
Light-activated CRISPR/dCas9 nanomedicine for programmable control of renal fibrosis
Taha, B. A., Addie, A. J., Haider, A. J., Ibnaouf, K., Apsari, R., & Arsad, N. (2026) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2026.113563 · Cited by 1
Zenke, M., Marx-Stölting, L., Schickl, H., & Verlagsgesellschaft, N. (2018) · Nomos Verlagsgesellschaft mbH & Co. KG eBooks · doi:10.5771/9783845287720 · Cited by 1
Onyejeme, P. C., Thanni, A. A., Ojo, T. J., Raymond, Q. C., Nwachukwu, O. U., Folaranmi, H. W., & Nwandu, H. O. (2025) · International Journal of Science and Technology Research Archive · doi:10.53771/ijstra.2025.9.1.0051 · Cited by 1
Azevedo, F., & Fischer, M. L. (2025) · Aracê. · doi:10.56238/arev7n9-061 · Cited by 1
Enhanced cleavage of genomic CCR5 using CasX2 Max
Hodge, C. A., Donegan, N. P., Armstrong, D. A., Hayden, M. S., & Howell, A. L. (2025) · RNA Biology · doi:10.1080/15476286.2025.2577449 · Cited by 1
From genomes to precision medicine: 25 years of breakthroughs in genetics and genomics
Hailu, S. G. (2026) · The Nucleus · doi:10.1007/s13237-025-00632-4 · Cited by 1
Galdikaitė, E., Krušnauskas, R., Henderson, E., & Bujakowska, K. M. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101462 · Cited by 1
Leandro, K., Rufino‐Ramos, D., Lopes, S. M., Silva, F. S., Rodrigues‐Santos, P., Silva, A. C., Fernandes, A. R., Henriques, C., Pereira, D., Lobo, D. D., et al. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124119 · Cited by 1
Insights from Stem Cell and CRISPR-Based Therapies for Diabetes Mellitus: A Systematic Review
Khalil, A. M. (2026) · OBM Genetics · doi:10.21926/obm.genet.2601329 · Cited by 1
Leveraging Auxiliary Potentials in RFDiffusion for the Design of NA-Binding Proteins
Geraseva, E., Bokov, G. V., Polovnikov, V., & Golovin, A. V. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00109 · Cited by 1
CRISPR in the Tumor Microenvironment: From Diagnostic Profiling to Precision Therapy
Zhou, L., Mu, M., Yang, M., Liu, X., Zou, G., & Liu, C. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i1.12 · Cited by 2
High-fidelity genome and prime editing enabled by the AI-designed openCRISPR-1
Hwang, H.-Y., Yi, H., Gwon, Y., Jeon, E. J., & Kim, D. (2026) · Genome Medicine · doi:10.1186/s13073-026-01682-2 · Cited by 2
Simhadri, V. L., Bajgain, P., Vijayanand, S., Jankowski, W., Rawal, A., Thijs, L., Doninck, T. V., Boonen, K., Pattyn, S., Pepermans, E., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75015-7 · Cited by 1
Cho, U., Pu, J., Sharma, A., Song, J., You, J. H., Kim, Y., Im, P. W., Park, H. W., Moon, H. E., Myeong, H. S., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02736-0 · Cited by 2
Zhang, Y., Yang, Y., Liu, Z., Li, Y., Xue, Y., Zhang, Z., Chen, G., Liu, J., He, M., Lu, T., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.08.006 · Cited by 1
Dong, S., Gong, F., Thomson, T., Cai, Y., Healy, L., Lu, R. X. Z., Zhou, Z., Xu, Y., Chen, J., Savguira, M., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03298-8 · Cited by 1
CRISPR-Mediated Gene Editing: A Revolutionary Strategy for Treatment of Cutaneous Diseases
Khalil, A. M. (2025) · Journal of Biomedical Advance Scientific Research · doi:10.63721/25jbasr0105 · Cited by 1
Second Generation Genome Editing Technologies in Drug Discovery
Malcolm, T., Mitchell, D. A., & Muni, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812034-7.00008-x · Cited by 1
Asghar, A., Asjad, Z., Tahir, H., Maheen, Z., & Hanif, S. (2021) · Pakistan Journal of Intensive Care Medicine · doi:10.54112/pjicm.v2021i1.6 · Cited by 1
CRISPR: A Promising Tool for Cancer Therapy
Mohammad‐Rafiei, F., Safdarian, E., Adel, B., Vandchali, N. R., Navashenaq, J. G., & Hayat, S. M. G. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220624111311 · Cited by 1
Applications and challenges for CRISPR/Cas9-mediated gene editing
Zhiyang, G. (2022) · AIP conference proceedings · doi:10.1063/5.0115407 · Cited by 1
Wang, Y., Wu, J., Wang, X., Kang, Y., Chu, C., Zeng, Y., Chen, Z., Zhao, Z., Chen, X., Tian, B., et al. (2023) · Life Medicine · doi:10.1093/lifemedi/lnad002 · Cited by 1
THE PROSPECTS AND CHALLENGES OF CRISPR/CAS9 GENE EDITING IN CANCER THERAPY: A LITERATURE REVIEW
ABDUSSADYK, D., & Beisenova, A. (2023) · Oncologia i radiologia Kazakhstana · doi:10.52532/2521-6414-2023-2-68-64-68 · Cited by 1
Therapeutic applications of CRISPR-Cas9 in diabetes mellitus: a perspective review
Bora, J., Malik, S., Kishore, S., Rustagi, S., Ahmad, F., Fagoonee, S., Pellicano, R., & Haque, S. (2024) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.23.02996-6 · Cited by 1
Advancements of CRISPR/Cas9 technology and its value in antiviral therapeutics
Dev, K., Begum, J., Mir, N. A., & Kant, R. (2021) · Letters In Animal Biology · doi:10.62310/liab.v1i1.60 · Cited by 1
Rao, J., Wang, X., Chen, X., Liu, Y., Jiang, J., & Wang, Z. (2024) · Gene · doi:10.1016/j.gene.2024.148760 · Cited by 1
Aoki, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102330 · Cited by 1
Bazazzadegan, N., Hasanzad, M., & Abedini, S. S. (2024) · Springer eBooks · doi:10.1007/978-981-97-4974-4_9 · Cited by 1
Technologies for In Utero Stem Cell Targeting
Borges, B., Lum, T., & MacKenzie, T. C. (2025) · Current Stem Cell Reports · doi:10.1007/s40778-025-00243-4 · Cited by 1
Engineering mucosal immunity: Advanced vaccine platforms against respiratory pathogens
Wang, M., Chang, Q., Li, B., Yang, R., Chen, X., Bai, Y., He, H., & Zheng, B. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100040 · Cited by 3
Curtis, B. C., Spurrell, C. H., Flint, L., Lande, A. M., Leonardi, M., Rosser, J. M., Parker, T., Chai, T., Valdez, A., Toumi, R., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103117 · Cited by 1
Geny, S., Hosseini, E. S., Concordet, J., & Giovannangeli, C. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015714-00400 · Cited by 1
CRISPR–Cas immune systems and genome engineering
Klompe, S. E., & Sternberg, S. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00012-x · Cited by 1
Application of genome editing technology in human gene therapy
Mitani, K. (2020) · Translational and Regulatory Sciences · doi:10.33611/trs.2020-007 · Cited by 1
Cell-Based Delivery Approaches for DNA-Binding Domains to the Central Nervous System
Deng, P., Halmai, J. A. N. M., Waldo, J. J., & Fink, K. D. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210517144044 · Cited by 2
Recent Progress in Genome Editing for Gene Therapy Applications: The French Perspective
Amendola, M., Bedel, A., Buj‐Bello, A., Carrara, M., Concordet, J., Frati, G., Gilot, D., Giovannangeli, C., Gutiérrez-Guerrero, A., Laurent, M., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.191 · Cited by 2
Role of CRISPR-Cas/9 in Hematological Disorders: A Review
Sharma, S. (2021) · Archives in Biomedical Engineering & Biotechnology · doi:10.33552/abeb.2021.05.000613 · Cited by 1
Immune Responses to Adeno-Associated Virus-Mediated CRISPR Therapy
Keeler, A. M. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29193.amk · Cited by 1
Applications of CRISPR-Cas System in Tumor Biology
Ma, M., Liu, Y., & Huang, W. (2021) · ONCOLOGIE · doi:10.32604/oncologie.2022.019415 · Cited by 1
In Utero Gene Editing for Inherited Lung Diseases
White, B. M., Morrisey, E. E., & Peranteau, W. H. (2022) · Current Stem Cell Reports · doi:10.1007/s40778-021-00205-6 · Cited by 1
Gene Therapy and Cell Therapy: Bioanalytical Challenges and Practical Solutions
Jani, D., Boyanapalli, R., & Cao, L. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-97193-9_5 · Cited by 1
Bioethical Decision-Making About Somatic Cell Genome Editing: Sickle-Cell Disease as a Case Study
Rudge, C., & Nicol, D. (2023) · Collaborative bioethics · doi:10.1007/978-3-031-29451-8_5 · Cited by 1
Chakraborty, S. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/252296 · Cited by 1
Metadata
- Authors
- Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., Behlke, M. A., Dejene, B., Cieniewicz, B., Romano, R., Lesch, B. J., Gomez-Ospina, N., Mantri, S., Pavel-Dinu, M., Weinberg, K. I., & Porteus, M. H.
- Affiliations
- Stanford Medicine (US)
- Integrated DNA Technologies (United States) (US)
- Corresponding author
- Weinberg, Kenneth I.
- Porteus, Matthew H.
- ORCID
- Charlesworth, Carsten T.
- Dever, Daniel P.
- Camarena, Joab
- Lemgart, Viktor T.
- Cromer, M. Kyle
- Vakulskas, Christopher A.
- Collingwood, Michael A.
- Zhang, Liyang
- Bode, Nicole M.
- Behlke, Mark A.
- Dejene, Beruh
- Cieniewicz, Brandon
- Romano, Rosa
- Lesch, Benjamin J.
- Gomez-Ospina, Natalia
- Mantri, Sruthi
- Pavel-Dinu, Mara
- Weinberg, Kenneth I.
- Porteus, Matthew H.
- Venue
- Nature Medicine
- Published
- 2019-01-28
- Volume
- 25
- Issue
- 2
- Pages
- 249-254
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC7199589
- OpenAlex
- W2949380898
- Cited by
- 1,093
- References
- 48
- Citations by year
- 2026: 130 · 2025: 128 · 2024: 132 · 2023: 111 · 2022: 125 · 2021: 166 · 2020: 131 · 2019: 110
- FWCI
- 44.16
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nd)
- Funders
- Amon G. Carter Foundation
- National Institutes of Health (5r01ai120766-02)
- National Institute of General Medical Sciences (T32GM119995)
- National Institute of Allergy and Infectious Diseases (R01-AI120766)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, SaCas9, SpCas9, Staphylococcus aureus, Streptococcus pyogenes, humoral immune response, cell-mediated immunity, genome editing safety
- MeSH terms
- CRISPR-Associated Protein 9, Adult, Cell Separation, Female, Humans, Male, T-Lymphocytes, Adaptive Immunity, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
